CareDx, Inc. Stock 12‑Month Price Target Raised to $86.17, Implies 20% Upside
CareDx, Inc.'s average stock price target increased to $86.17 from $65.33, with estimates ranging from $46 to $100 per share. This implies a 20% upside based on the Oct. 29 closing price. The consensus rating remains 'Buy' among 7 analysts, with 5 Buys and 2 Holds.
How this was made

The 30-second read
Why it matters
Analyst consensus remains a Buy, reinforcing the positive outlook.
Market read
Analyst price target upgrade may attract short-term buying interest.
What to watch
No new product or trial news accompanies the target raise.
Background
CareDx is a molecular diagnostics company focused on transplant monitoring.
Ticker impact
Analysts raised CareDx's average price target to $86.17, implying ~20% upside.
upward pressure as investors price in the higher target.
The new target reflects improved analyst outlook; no new fundamentals disclosed.
Market effects
May lift sentiment in the biotech diagnostics sector.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
Target could be premature if upcoming trial data disappoints.
Key entities
- companyCareDx, Inc.
Molecular diagnostics firm.


